A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18
(2002) Tissue Antigens : immune response genetics — Vol. 60, n° 1, p. 16-24 (2002)
Files
BILS_TA2002.pdf
Restricted Access - Adobe PDF
- 261.15 KB
Details
- Authors
- Abstract
- Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their tumoral specificity and because they are shared by many tumors. Antigenic peptide MEVDPIGHLY, which is encoded by MAGE-3 and is known to be presented by human leukocyte antigen (HLA)-B44, is currently being used in therapeutic vaccination trials. We report here that a cytolytic T lymphocyte (CTL) clone, which is restricted by HLA-B*1801, recognizes the same peptide and, importantly, lyzes HLA-B18 tumor cells expressing MAGE-3. These results imply that the use of peptide MEVDPIGHLY can now be extended to HLA-B18 patients. We also provide evidence that, under limiting amounts of protein MAGE-3, HLA B*1801 and B*4403 compete for binding to the peptide.
- Affiliations
Citations
Bilsborough, J., Panichelli, C., Duffour, M., Warnier, G., Lurquin, C., Schultz, E., Thielemans, K., Corthals, J., Boon, T., & van der Bruggen, P. (2002). A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens : immune response genetics, 60(1), 16-24. https://doi.org/10.1034/j.1399-0039.2002.600103.x (Original work published 2002)